GT Biopharma, Inc.
GTBP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2,311 | $9,923 | $5,042 | $5,786 |
| - Cash | $2,528 | $5,228 | $2,365 | $3,951 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$217 | $4,695 | $2,677 | $1,835 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$3,114 | -$1,433 | -$776 | -$3,775 |
| % Margin | – | – | – | – |
| Net Income | -$3,114 | -$1,433 | -$776 | -$3,775 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.83 | -0.55 | -0.33 | -1.99 |
| % Growth | -50.9% | -66.7% | 83.4% | – |
| Operating Cash Flow | -$3,677 | -$3,014 | -$2,202 | -$2,468 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3,677 | -$3,014 | -$2,202 | -$2,468 |